Valneva SE signed an advance purchase agreement with the Kingdom of Bahrain for the supply of one million doses of the Company’s inactivated COVID-19 vaccine candidate VLA2001. This is the second purchase agreement Valneva has secured for VLA2001 since reporting positive data for its Phase 3 clinical trial Cov-Compare.   Valneva has initiated a rolling submission process with the Bahraini National Health Regulatory Authority (NHRA).   Franck Grimaud, Chief Business Officer of Valneva, commen...